Drugs for atrial fibrillation

Med Lett Drugs Ther. 2019 Sep 9;61(1580):137-144.
No abstract available

Keywords: Antiarrythmic Drugs; Beta-adrenergic blockers; Betapace; Brevibloc; Calan; Cardizem; Cartia; Catheter Ablation; Coreg; Corgard; Coumadin; DOAC; Digitek; Digox; Eliquis; Inderal; InnoPran; Isoptin; Kapspargo Sprinkle; Lanoxin; Lixiana; Lopressor; Mephyton; Multaq; NOAC; Norpace; Pacerone; Pradaxa; Praxbind; Rate Control; Rhythm Control; Rythmol; Savaysa; Sotalol; Taztia; Tenormin; Tiazac; Tikosyn; Toprol; Verelan; Xarelto; adverse effects; amiodarone; andexanet alfa; anticoagulants; apixaban; atenolol; atrial fibrillation; beta blockers; bisoprolol; calcium-channel blockers; carvedilol; dabigatran; digoxin; diltiazem; disopyramide; dofetilide; dosage; dronedarone; drug interactions; edoxaban; efficacy; esmolol; flecainide; idarucizumab; metoprolol; nadolol; propafenone; propranolol; rivaroxaban; safety; sotalol; verapamil; vitamin K; warfarin; weight loss.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / pharmacokinetics
  • Adrenergic beta-Antagonists / therapeutic use*
  • Animals
  • Anti-Arrhythmia Agents / pharmacokinetics
  • Anti-Arrhythmia Agents / therapeutic use*
  • Anticoagulants / pharmacokinetics
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / metabolism
  • Calcium Channel Blockers / pharmacokinetics
  • Calcium Channel Blockers / therapeutic use*
  • Clinical Trials as Topic / methods
  • Dabigatran / pharmacokinetics
  • Dabigatran / therapeutic use
  • Humans
  • Rivaroxaban / pharmacokinetics
  • Rivaroxaban / therapeutic use

Substances

  • Adrenergic beta-Antagonists
  • Anti-Arrhythmia Agents
  • Anticoagulants
  • Calcium Channel Blockers
  • Rivaroxaban
  • Dabigatran